企業プロフィール
Genmab 株価・ニュース・カタリスト
- ティッカー:
- GMAB
- 取引所:
- NASDAQ
- セクター:
- Antibody Drugs
- 所在地:
- Copenhagen, Denmark
株価パフォーマンス
32.84 USD (+2.82%)
終値
最終更新: 2026年8月17日
14.6B USD
時価総額
株価変動の要因
As of Aug 17, 2026, GMAB closed up 2.82% at $32.84. No new same-company headline was identified in the current news window.
企業概要
事業概要
Genmab is an antibody-focused biotechnology company with a long record of discovering and advancing differentiated cancer therapeutics. The company is known for its antibody engine, its partnered programs, and its ability to turn discovery into commercial or royalty-based value.
所在地とセクター分類
Headquartered in Copenhagen, Denmark and listed on Nasdaq Copenhagen and as an ADR in the U.S., Genmab is a global biotechnology company. Its footprint spans Europe and the United States.
ビジネスモデルの特徴
Genmab combines internal R&D with partnered programs, milestone revenue, and royalty income from successful antibodies. Investors follow clinical data, partner progress, and whether the company can keep producing validated antibodies from its discovery platform.
バイオ業界での位置付け
Genmab sits in the premium end of antibody biotech because it has both scientific credibility and economic leverage from partnerships. The stock can move on data, deal flow, or royalty updates, making it a platform-driven catalyst name.
今後のカタリスト
- Genmab’s next three months are likely to focus on epcoritamab, combination data, and any label or expansion steps that deepen the antibody franchise. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。